ROIV (Roivant Sciences Ltd. Common Shares) stock: $38.85, $28.06B market cap, $3.84B cash, $24.22B EV, $28.08B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$38.85
Market cap
$28,062.2M
Cash
$3,842.1M
Enterprise value
$24,220.1M
Balance sheet
Cash
$3,842.1M
Debt
$0.0M
Net cash
$3,842.1M
Enterprise value
$24,220.1M
Basic shares
722.7M shares
Fully diluted shares
722.7M shares
Fully diluted market cap
$28,076.9M
Cash per share
$5.32
Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading ROIV daily closes…
Loading price history…
Pipeline assets
IMVT-1402
Stage not disclosed · ActiveModality: monoclonal antibody
Target FcRn
Partnerships HanAll Biopharma: core IP rights via the HanAll Agreement (Immunovant subsidiary)
Indications
Graves' disease (GD)(Stage not disclosed)
Difficult-to-treat rheumatoid arthritis (D2T RA)(Stage not disclosed)
Lichen planopilaris (LPP)(Stage not disclosed)
Status note Anti-FcRn antibody; the company's lead development program following discontinuation of batoclimab. Trials ongoing in D2T RA and other indications; filing references a potential launch in Graves' disease. No trial phase stated in the provided excerpts.
Brepocitinib
Phase 3 · ActiveModality: small molecule
Target TYK2/JAK1
Partnerships Priovant (Roivant Vant); originally developed by Pfizer (other brepocitinib studies conducted by Pfizer)
Indications
Dermatomyositis (DM)(Phase 3)
Lichen planopilaris (LPP)(Phase 3)
Cutaneous sarcoidosis (CS)(Phase 2)
Catalysts
— None
— None
— None
Status note Oral TYK2/JAK1 inhibitor. FDA accepted the NDA in DM with Priority Review (target action date Q3 2026). Seamless Phase 2b/3 potentially registrational trial in LPP enrolled first subjects. Breakthrough Therapy Designation for cutaneous sarcoidosis (Phase 2 BEACON study complete).
Batoclimab
Phase 2 · TerminatedModality: monoclonal antibody
Target FcRn
Partnerships HanAll Biopharma: HanAll Agreement
Status note The company discontinued further development of batoclimab across all indications to focus fully on IMVT-1402.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
Baker Bros. Advisors
4,716,831
-150,892
0.84%
2026-08-14
ADAR1 Capital Management
3,157,008
-128,898
5.25%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.